|
TRIFLUORPERAZINE DIHYDROCHLORIDE | ||
PRODUCT IDENTIFICATION |
||
CAS NO. | 117-89-5
(Base) 440-17-5 (Dihydrochloride |
|
EINECS NO. | 204-219-4, 207-123-0 | |
FORMULA | C21H24F3N3S·2HCl | |
MOL WT. | 480.42 | |
H.S. CODE |
||
TOXICITY |
||
SYNONYMS | Stelazine; Trifluoperazine; Trifluorperazine; | |
3-Trifluromethyl-10-[3-(4-methyl-1- piperazinyl)-propyl] phenothiazine; 10-[3-(4-methyl-1 -piperazinyl) propyl]-2-(trifluoromethyl) phenothiazine dihydrochloride; | ||
SMILES |
|
|
CLASSIFICATION |
||
PHYSICAL AND CHEMICAL PROPERTIES |
||
PHYSICAL STATE | white to yellowish crystalline powder | |
MELTING POINT | ||
BOILING POINT |
| |
SPECIFIC GRAVITY |
| |
SOLUBILITY IN WATER | ||
pH | ||
VAPOR DENSITY |
| |
REFRACTIVE INDEX |
| |
NFPA RATINGS |
||
AUTOIGNITION |
| |
FLASH POINT |
| |
STABILITY | Stable under normal conditions. Hygroscopic. | |
APPLICATIONS |
||
Trifluorperazine is a short-acting piperazine phenothiazine antipsychotic drug which exhibits a more propensity for producing extrapyramidal reactions than the group of phenothiazine antipsychotic drugs, and used orally and intramuscularly. It may occur less hypertension but less potentiating effect on CNS depressants, anesthetics sedating than the group of phenothiazine antipsychotic drugs. | ||
SALES SPECIFICATION (USP) | ||
APPEARANCE |
white to yellowish crystalline powder |
|
IDENTIFICATION |
pass Test A, B |
|
ASSAY |
99.0 - 101.0% |
|
LOSS ON DRYING |
0.5% max |
|
SULFATED ASH |
0.1% max |
|
INDIVIDUAL IMPURITY |
0.2% max (total 0.5% max) |
|
HEAVY METALS |
10ppm max |
|
TRANSPORTATION | ||
PACKING | small
and bulk | |
HAZARD CLASS | ||
UN NO. | ||
OTHER INFORMATION | ||
Hazard Symbols: XN, Risk Phrases: 22, Safety Phrases: 36 | ||
GENERAL DESCRIPTION OF ANTIPSYCHOTIC AGENTS |
||
The term antipsychotic refers to a group of drugs effective in the treatment of
psychosis including schizophrenic, paranoid, schizoaffective, bipolar disorder,
and other psychotic disorders. Traditional antipsychotic agents have
phenothiazine structure chemically. Phenothiazinene drugs are adrenergic
blocking agents. Their pharmacologic actions including central nervous system
depression, prolongation and potentiation of the effects of narcotic and
hypnotic drugs, hypotensive activity, and antispasmodic, antihistaminic, and
antiemetic activity. Other chemcial structures for antipsychotic drugs are
diverse, they include thioxanthene, butyrophenone, dibenzoxazepine,
dihydroindolone, benzisoxazole, and diphenylbutylpiperidine. Antipsychotic
agents bind to dopamine, histamine, muscarinic cholinergic, a-adrenergic, and
serotonin receptors. Blockade of dopaminergic transmission in various areas is known
to be responsible for their major effects such as not
only antipsychotic action by
blockade in the mesolimbic and mesocortical areas and and antiemetic effects by blockade in the chemoreceptor trigger
zone of the medulla but also extrapyramidal side effects
(dystonia, akathisia, parkinsonism, and tardive dyskinesia) by blockade in the
basal ganglia and sedation and autonomic side effects (orthostatic
hypotension, blurred vision, dry mouth, nasal congestion, and constipation) by blockade of histamine, cholinergic, and adrenergic receptors.
The antipsychotic agents may be divided by chemical group and and the decreased propensity of extrapyramidal side effects
into two main groups and a new class which is being
processed.
|
||
PRICE INFORMATION | ||
|
|